A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 68,300 shares of GRTS stock, worth $2,049. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,300
Previous 34,600 97.4%
Holding current value
$2,049
Previous $21,000 85.71%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.62 - $2.35 $59,772 - $226,556
-96,407 Reduced 58.72%
67,786 $42,000
Q1 2024

May 15, 2024

SELL
$1.96 - $2.9 $275,142 - $407,099
-140,379 Reduced 46.09%
164,193 $421,000
Q4 2023

Feb 14, 2024

SELL
$1.28 - $2.85 $61,653 - $137,275
-48,167 Reduced 13.66%
304,572 $621,000
Q3 2023

Nov 14, 2023

SELL
$1.19 - $2.26 $104,254 - $197,996
-87,609 Reduced 19.9%
352,739 $606,000
Q2 2023

Aug 14, 2023

SELL
$1.66 - $3.03 $194,912 - $355,773
-117,417 Reduced 21.05%
440,348 $858,000
Q1 2023

May 15, 2023

BUY
$2.13 - $3.74 $361,993 - $635,613
169,950 Added 43.82%
557,765 $1.55 Million
Q4 2022

Feb 14, 2023

SELL
$2.17 - $3.92 $125,415 - $226,556
-57,795 Reduced 12.97%
387,815 $1.34 Million
Q3 2022

Nov 14, 2022

SELL
$2.46 - $4.75 $146,067 - $282,040
-59,377 Reduced 11.76%
445,610 $1.15 Million
Q2 2022

Aug 15, 2022

SELL
$1.77 - $4.34 $238,080 - $583,769
-134,509 Reduced 21.03%
504,987 $1.22 Million
Q1 2022

May 16, 2022

BUY
$4.03 - $12.19 $1.18 Million - $3.56 Million
292,415 Added 84.25%
639,496 $2.64 Million
Q4 2021

Feb 14, 2022

BUY
$8.76 - $13.71 $1.17 Million - $1.84 Million
133,961 Added 62.86%
347,081 $4.46 Million
Q3 2021

Nov 15, 2021

BUY
$6.41 - $13.54 $1.15 Million - $2.43 Million
179,619 Added 536.16%
213,120 $2.3 Million
Q2 2021

Aug 16, 2021

SELL
$8.13 - $10.2 $3.39 Million - $4.25 Million
-416,695 Reduced 92.56%
33,501 $305,000
Q1 2021

May 17, 2021

BUY
$4.07 - $27.11 $1.83 Million - $12.2 Million
450,196 New
450,196 $4.25 Million
Q3 2020

Nov 16, 2020

SELL
$2.63 - $8.09 $204,482 - $628,997
-77,750 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$5.69 - $8.17 $131,268 - $188,481
-23,070 Reduced 22.88%
77,750 $517,000
Q1 2020

May 15, 2020

BUY
$5.47 - $11.3 $31,282 - $64,624
5,719 Added 6.01%
100,820 $587,000
Q4 2019

Feb 14, 2020

BUY
$7.07 - $11.61 $33,405 - $54,857
4,725 Added 5.23%
95,101 $853,000
Q3 2019

Nov 14, 2019

SELL
$8.45 - $12.28 $480,297 - $697,995
-56,840 Reduced 38.61%
90,376 $780,000
Q2 2019

Aug 14, 2019

BUY
$9.2 - $15.7 $684,434 - $1.17 Million
74,395 Added 102.16%
147,216 $1.64 Million
Q1 2019

May 15, 2019

BUY
$9.97 - $18.96 $602,686 - $1.15 Million
60,450 Added 488.64%
72,821 $0
Q4 2018

Feb 14, 2019

SELL
$11.61 - $31.1 $602,965 - $1.62 Million
-51,935 Reduced 80.76%
12,371 $191,000
Q3 2018

Nov 13, 2018

BUY
$14.24 - $14.24 $915,717 - $915,717
64,306 New
64,306 $0

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.